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Abstract: This paper describes the optimization and validation of an analytical method for the determination of 83 13 
pharmaceutically active compounds (PhACs) in aqueous samples using solid-phase extraction (SPE) followed by 14 
ultra performance liquid chromatography-triple quadrupole mass spectrometry (UPLC-QqQ-MS/MS). First, several 15 
experiments were conducted to optimize different SPE extraction parameters such as pH, elution solvents, and 16 
Na2EDTA addition. Extraction recovery percentages were between 17 and 146%, being higher than 70% for 47 target 17 
analytes. The method limits of detection (LOD) and quantification (LOQ) were below 1 ng L-1 for most compounds 18 
(> 90%), and the precision of the method, calculated as the relative standard deviation (RSD) of replicate extractions 19 
and analyses, was less than 20%. The optimized method was successfully applied to the analysis of real water 20 
samples in estuarine and coastal systems from SW Spain (Cadiz Bay and Huelva Estuary). 49 out of 83 target 21 
compounds were found in 75% of samples. Ibuprofen, atenolol, gemfibrozil and caffeine were the most commonly 22 
substances detected, reaching concentrations up to 195 ng L-1. These are among the first data available on the 23 
occurrence of a wide range of pharmaceuticals in European coastal waters. 24 
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1. INTRODUCTION 28 
Recent studies have demonstrated that a combination of the widespread use of pharmaceuticals 29 
(PhACs) and their relative inefficient removal in wastewater treatment plants (WWTPs) leads to the 30 
detection of low concentrations of these chemicals (sub-ppb levels) in most sewage-impacted aquatic 31 
systems [1-4]. The presence of pharmaceutically active compounds (PhACs) in the receiving waters is 32 
concerning as it can represent a threat not only for humans through drinking water intake [5-6] or 33 
development of antibiotic-resistant bacteria [7], but also for aquatic organisms [8]. At the same time, 34 
chronic and acute toxicity caused by PhACs and other organic micro-contaminants is an open question. 35 
Most recent studies have reported behavioral and physiologic alterations in aquatic organisms exposed to 36 
sub-lethal concentrations of PhACs during short periods of time [9-11]. The occurrence of long-term 37 
effects, however, is still widely unknown, as are the synergism and/or antagonism in toxicity of mixtures 38 
and the role of secondary products that could be even more harmful than parent PhACs [12].  39 
The presence of a wide range of PhACs in surface waters at very low concentrations has led to the 40 
development of several multiresidue methods for their analysis over the last decade, most of them relying 41 
on a preconcentration stage and later determination of target compounds by liquid chromatography–mass 42 
spectrometry (LC-MS) [13-16]. The preconcentration step is mandatory not only for achieving lower 43 
detection limits but also in order to minimize matrix effects during LC-MS analysis [18-19]. The most 44 
commonly used extraction technique for isolation of PhACs is solid phase extraction (SPE) [20-22]. This 45 
technique offers the possibility of automation (e.g., online SPE) to minimize sample manipulation and 46 
induced errors [5, 23]. Several studies have tested different cartridge types –octadecylsilica (C18), Isolute 47 
ENV+, Oasis MCX, Lichrolut EN, and Oasis HLB, among others- for isolating PhACs, all of them 48 
showing positive results for some groups such as most anti-inflammatories, lipid regulators or 49 
sulfonamides [24-26, 15].  Extraction recoveries reported for the non-polar sorbent C18 have been 50 
acceptable for most compounds, but these values are generally 20% below those obtained with Oasis 51 
HLB. Isolute ENV+, on the other hand, is only adequate for a narrow range of substances, mostly polar 52 
acidic organic compounds. It is also able to retain some neutral analytes such as macrolide antibiotics, 53 
achieving similar recoveries (80%) than those for Oasis HLB cartridges [25, 26]. Lichrolut EN has been 54 
successfully applied for extraction of aqueous samples at neutral pH but recoveries are poor (< 50%) for 55 
some antibiotics [24, 26]. Oasis MCX cartridges are not effective [25] unless samples are acidified first, 56 
showing an enhancement in recovery percentages between 20 and 40% for basic drugs such as 57 
glibenclamide, trimethoprim and metronidazole [15]. Overall, some sorbents are better for specific 58 
compound families such as penicillins, where an improvement of up 36% for amoxicillin can be observed 59 
using Oasis MCX cartridges instead of other sorbents [24]. Psychiatric drugs like fluoxetine show 60 
recoveries up to 100% when employing octadecylsilica cartridges [25]. Better recoveries, however, are 61 
often achieved for the majority of tested analytes and conditions (water samples at acid and basic pH 62 
values) using Oasis HLB cartridges, the most popular option when developing multiresidue methods [15].  63 
Regarding LC-MS analysis of PhACs, the most successful technique over the last decade has been the 64 
triple quadrupole (QqQ) detector coupled either with high- or ultra-performance liquid chromatography 65 
(HPLC/UPLC). This instrument can determine environmentally relevant concentrations (sub-ppb) of 66 
organic trace substances such as PhACs via target analysis in multiple reaction monitoring mode (MRM) 67 
[25, 27, 15]. However, with increasing sensitivity, high resolution mass spectrometry (HR-MS) 68 
instruments (Orbitrap and time-of-flight mass analyzers, or ToF) are used increasingly to analyze a wide 69 
range of target and non-target micro-pollutants at trace levels [28]. Several methods using ToF-MS have 70 
been recently developed by our group for the analysis of surfactants such as secondary alkane sulfonates 71 
(SAS) and nonionic compounds at detection limits below 30 ng L
-1
 in coastal waters [29, 30]. In addition, 72 
Hollender and co-workers [31] have analyzed 220 micropollutants in water using HR-MS, including a 73 
variety of pharmaceuticals (sulfonamides, antiinflamatories, and lipid regulators) and pesticides, with 74 
detection limits as low as 0.1 ng L
-1
 for specific chemicals such as trimethoprim, being lower than 120 ng 75 
L
-1
 for most PhACs.  76 
In spite of a significant increase in the number of reports on the environmental distribution and 77 
concentrations of PhACs in aquatic systems [32], most of the information is heavily biased towards 78 
freshwater systems and WWTP removal efficiency [33, 34]. Coastal environments have usually received 79 
less attention in the research not only on PhACs but also on other polar organic micropollutants [35-39]. 80 
So far, concentrations of up to 50 ng L
-1
 have been reported for lipid regulators (clofibric acid) and anti-81 
inflammatories (diclofenac and ibuprofen) in coastal waters from Taiwan [38]. In addition, near 200 ng L
-82 
1
 were detected for carbamazepine in the Baltic Sea and for atenolol in samples from Aegean Sea and 83 
Dardanelles in Greece and Turkey, respectively [39]. The behavior and removal of these compounds in 84 
coastal systems, however, is not clear, especially in more complex systems such as estuaries, where many 85 
processes can influence the reactivity of PhACs [40]. For instance, microbial [41] or sunlight degradation 86 
[42] of compounds such as propanolol and indomethacin can shorten their half-lives to < 24 hours. On the 87 
other hand, a constant concentration with no decline has been reported for some substances such as 88 
sulfamethoxazole and carbamazepine [37, 43, 39] which can be considered as highly persistent 89 
wastewater markers in coastal water. The aim of this paper is therefore to provide a better knowledge of 90 
the occurrence, concentrations and distribution of a wide range of PhACs in coastal systems. First, we 91 
have explored several aspects of the extraction and preconcentration of pharmaceuticals in aqueous 92 
samples using SPE under different conditions. Separation, identification and quantification of target 93 
pharmaceuticals have been then carried out by a new generation UPLC-QqQ-MS/MS system. Once 94 
optimized, the developed method has been applied to the analysis of pharmaceutical residues in surface 95 
water samples taken from two different systems located in SW Spain (Cadiz Bay and Huelva Estuary) 96 
where no information on these compounds was available. 97 
 98 
2. EXPERIMENTAL SECTION 99 
2.1. Material and standards 100 
Methanol and acetonitrile were of chromatography quality and purchased from Scharlau (Barcelona, 101 
Spain); formic acid (98%), ammonia (25%), ammonium formate (97.8%), ammonium acetate (97%), 102 
hydrochloric acid (37%), sodium hydroxide (98%), acetic acid (99%) and Na2EDTA (99%) were 103 
purchased either from Sigma Aldrich (Madrid, Spain) or Panreac (Barcelona, Spain). Water was Milli-Q 104 
quality and the solid-phase extraction (SPE) mini-columns used (60 and 500 mg) were supplied by 105 
Waters (Oasis HLB cartridges, Waters Corp., Milford, MA). Analytical standards (> 95% purity) and 106 
deuterated or 13C-labelled surrogates used for quantification were obtained from several suppliers listed 107 
in Table 1. 108 
 109 
2.2. Sampling areas 110 
Surface water samples were taken from Cadiz Bay and Huelva Estuary (SW Spain) in October 2011 111 
using 2.5 L pre-washed amber glass bottles. Samples were kept < 4ºC during their transport to the 112 
laboratory, where they were filtered using 1 µm glass fiber filters (Pall Corporation, Madrid, Spain) and 113 
processed immediately. Huelva Estuary is located at the confluence of the Odiel and Tinto rivers (128 and 114 
100 km long, respectively), which forms a coastal wetland known as Ría of Huelva Estuary. This estuary 115 
is within a natural protected area (Marismas del Odiel) and flows into the Atlantic Ocean (37º7'47.22"N, 116 
6º50'51.59"). The province of Huelva has 142 284 inhabitants and the estuary system covers more than 117 
7000 hm
2
 between counties of Huelva and Punta Umbría (Fig. 1a). This area is also strongly affected by 118 
acid mine drainage due to ancient mining activity that produces an important background metal pollution 119 
[44]. Cadiz Bay is also situated in the southwest of the Iberian Peninsula and contains five different 120 
counties (Cadiz, Chiclana, El Puerto de Santa María, Puerto Real, and San Fernando) with nearly 435000 121 
inhabitants. The area is characterized by coastal marshes, estuaries and tidal creeks such as Río San Pedro 122 
and Sancti Petri. In addition, the bay hosts five ports and several shipyards. Most of this marshy area is 123 
part of a natural park (Bahía de Cádiz). Guadalete river (157 km long) flows across the province of Cadiz 124 
entering the sea in the northern part of the Bay of Cadiz at El Puerto de Santa María (89 068 inhabitants) 125 
(Fig. 1b). Most of the terrain adjacent to the river is used for agriculture, and there are also wastewater 126 
discharges from a WWTP located upstream [45, 46]. 127 
 128 
2.3. Sample extraction and purification by SPE 129 
Target compounds were extracted from water samples by SPE. Different operational conditions were 130 
compared to optimize the extraction method by spiking water aliquots at different concentrations (1-2.5 131 
ng L
-1
) using a standard mixture of target substances. First, two Oasis HLB cartridge types were tested 132 
(60 and 500 mg), as well as five different pH values (2, 4, 6, 8 and 10) by adding hydrochloric acid and/or 133 
sodium hydroxide to water samples. Additionally,  four different amounts of Na2EDTA (0, 0.5, 1 and 2.5 134 
g L
-1
) and five different elution solvents (methanol, acetonitrile, methanol 1% formic acid, methanol 1% 135 
ammonium acetate and ethylacetate-acetone 1:1) were also tested. All recovery experiments were 136 
performed by analyzing spiked water samples in triplicate (n=3). 137 
Once the SPE methodology was optimized, samples from Cadiz Bay and Huelva Estuary were 138 
processed by taking two 200 mL aliquots (one of them acidified to pH 2.5) from each surface water 139 
sample and spiking them to 50 µg L
-1
 using surrogates (Table 1) prior SPE. HLB cartridges (500 mg) 140 
were conditioned using 8 mL of methanol and 8 mL of water. Thereafter, the samples were passed 141 
through the SPE columns at 2 mL min
-1
. The sorbent was washed with 10 ml water and air-dried for 20 142 
min. Elution was performed with pure methanol (10 mL). The extracts were evaporated under a gentle 143 
stream of nitrogen, reconstituted in a methanol/water mixture (25:75) and filtered using 0.22 µm 144 
polytetrafluoroethylene (PTFE) filters (Teknochroma, Barcelona, Spain).  145 
 146 
2.4. Triple quadrupole mass spectrometry detection 147 
Analysis of compounds was carried out by UPLC-QqQ-MS/MS using a Bruker EVOQ Elite system 148 
(Bruker, Billerica, MA). The injection volume was set to 10 µl. The chromatographic separation was 149 
performed on a reverse-phase C18 analytical column (Intensity Solo HPLC Column) of 100 mm x 2.1 150 
mm and 2 µm particle size. Several mobile phases and additives at different concentrations were tested to 151 
optimize peak shapes and intensities, as well as chromatographic separation for compounds acquire under 152 
both positive and negative electrospray modes (ESI+/-). Aqueous mobile phase additives consisted in 153 
formic acid (0.1, 0.01%, and 10 mM) and ammonium formate (10 mM) for positive ionization and acetic 154 
acid (0.1% and 0.01%), ammonium acetate and ammonia (5 mM) for negative ionization combined with 155 
methanol and acetonitrile as organic solvents. The best results were obtained using methanol (solvent A) 156 
as organic phase and water with 10 mM of formic acid and ammonium formate or 5mM of ammonium 157 
acetate and ammonia as aqueous phases (solvent B) for ESI- and ESI+, respectively (flow rate = 0.4 mL 158 
min
-1
). The elution gradient for positive mode started at 5% of solvent A. The percentage of methanol was 159 
then increased linearly to 100% during the first 5 min, and kept at 100% over 3 min. Total run time was 160 
10 min including a re-equilibration time of 2 min. Initial conditions were similar operating in negative 161 
mode increasing the amount of methanol linearly to 100 % in 2 min, keeping it at 100% during 4 min and 162 
then, back to initial conditions within 2 min (overall run time = 8 min).  163 
The MS system used the following settings: source temperature = 250ºC, probe temperature = 450 ºC, 164 
cone gas flow = 20 mL min
-1
, probe gas flow = 50 mL min
-1
, nebulizer gas flow = 60 mL min
-1
, collision 165 
gas pressure = 2.0 mTorr. The ion spray voltage was 4500 V and 4200 V for ESI+ and ESI- mode, 166 
respectively. Standard solutions (1 g L
-1
) of each individual substance were infused to get the optimal 167 
collision energy. Optimization of cone voltages was not required unlike in other MS/MS systems [27] as 168 
the EVOQ instrument includes a special feature (flat-tunning) that maximizes the sensitivity. MRM 169 
transitions were monitored in 2 min windows to get the highest sensitivity and enough points per 170 
chromatographic peak (15). Scan time was at least 12 ms for each compound, achieving a total scan time 171 
between 0.6 (ESI-) and 1 s (ESI+). Identification of compounds was based on comparing their retention 172 
times to those previously obtained using standards. In addition, two MRM transitions were used to 173 
confirm the compound identity, considering also a deviation in the ion ratio between both transitions 174 
lower than 20%. However, only one product ion could be obtained for tetracycline, azithromycin and 175 
amitriptyline (Table 1). Quantification was performed using the MRM transition showing the highest 176 
intensity and using a calibration curve prepared with standards at concentrations ranging from 0.1 to 100 177 
µg L
-1
. Deuterated or 13C-labelled compounds were also used to correct for losses during the extraction 178 
process and matrix effects. The method limits of detection (mLOD) and quantification (mLOQ) were 179 
determined from 200 mL spiked water samples as the minimum detectable amount of analytes with a 180 
signal to noise ratio of 3 and 10 respectively. Instrument limits of detection (iLOD) were also calculated 181 
taking into account the amount of sample injected (10 µL). The repeatability and reproducibility of the 182 
method was checked through three successive injections of the same sample and re-analyzing a batch of 183 
samples and standards one week after their first analysis. All the data were acquired and processed using 184 
MS Workstation 8.1. Software. 185 
 186 
3. RESULTS AND DISCUSSION 187 
3.1. Solid phase extraction optimization for aqueous samples 188 
Figure 2 shows the SPE extraction efficiencies for some of the most representative target compounds 189 
during different experiments. First, Oasis HLB cartridges were chosen based on numerous studies that 190 
consider that sorbent optimal when developing a multi-residue method for PhACs [47, 25, 48]. Two 191 
different cartridges were compared (60 and 500 mg), and lower recoveries were found for those having 60 192 
mg of sorbent. This could be due to lower retention of target compounds proportional to the sorbent 193 
amount. Two examples are sulfamethazine and indomethazine, whose recovery percentages were reduced 194 
by 40% when using 60 mg cartridges instead of 500 mg (Figs. 2a and b). Once 500 mg Oasis HLB 195 
cartridges were considered for the next experiments, the effect of pH in water samples was tested by 196 
selecting a wide range of pH values (from 2 to 10). Better extraction efficiencies were obtained in 197 
samples at acid (pH 2-3) and neutral (pH 7) conditions. These results can be explained by considering that 198 
many antibiotics present acidic functional groups, therefore lowering pH by 2 units under their pKa 199 
values enhances the presence of neutral forms and their interaction with the HLB sorbent [49, 1, 22] (Fig. 200 
2c). In this sense, many antibiotic groups considered here showed better results at acid conditions, 201 
particularly fluoroquinolones (pKa values between 5 and 6) [20, 50, 16, 51]. The importance of acidic 202 
media for the extraction was also reflected for tetracyclines, increasing their recoveries up to 60% when 203 
comparing with neutral conditions [22]. Accordingly, acid conditions produced an extraction 204 
improvement in flumequine (15%) and tetracycline (27%) in this study (Figs. 2 b and c). Nevertheless, 205 
there is a significant fraction of target PhACs where no pH adjustment yields higher extraction 206 
efficiencies [25] (Table 2). Keeping neutral pH proved to be very critical for some substances such as 207 
macrolides (erythromycin) and sulfonamides (sulfadimethoxine) [51, 25, 1] as extraction efficiency 208 
decreased ≥40 and 90%, respectively, at lower pH values (Figs. 2 b and c).  209 
Previous studies pointed out the importance of a cation complexing agent (Na2EDTA) addition to 210 
avoid chelation of metals and to minimize interferences for some antibiotics such as macrolides [52] or 211 
tetracyclines [53, 17]. The use of acidic elution solvents was also explored. However, extraction 212 
efficiencies did not increase significantly (p < 0.05) when Na2EDTA was added in our case. In fact, there 213 
was a decrease up to 15% in recoveries for tetracycline and albuterol at pH 2-3 and 7, respectively. 214 
Recoveries stayed similar or were even lower for other compounds when EDTA was added. Two 215 
examples are erythromycin and indomethacin, whose extraction efficiencies decreased between 46 and 216 
62% (Fig 2 b to e). At the end, addition of chelating agent, acid and neutral pH conditions and methanol 217 
as elution solvent was not chosen to achieve higher recovery percentages for most of the PhACs. Table 2 218 
shows the SPE extraction efficiencies for all target compounds once the method was optimized. At least 219 
half of the target compounds exhibit recoveries that exceed 80 %, and about 80 % of PhACs show 220 
extraction efficiencies ≥50%. The choice of two different pH values was justified because of the wide 221 
range of compounds selected and their very different physicochemical properties (especially in terms of 222 
pKa values). This can be illustrated by considering flumequine and chloramphenicol, whose extraction 223 
recoveries were 29% and 50% higher at acid and neutral pH values, respectively (Figs. 2b and d). Many 224 
of the tested drugs, however, were not affected by pH changes (e.g., trimethoprim, atenolol, 225 
amitriptyline), presenting a RSD in their extraction efficiencies ≤15% when comparing both acid and 226 
neutral conditions (Figs. 2c and b). The same tendency was observed for other chemicals when 227 
considering adding Na2EDTA, such as tetracycline or chloramphenicol (Figs. 2c and e). Compared to 228 
previous studies, the relatively lower recoveries obtained by our group for cephalosporines are 229 
nevertheless comparable to those obtained by other researchers that report similar values for this group 230 
(around 40%) when extracting aqueous samples at neutral pH [26]. Regarding penicillins, our method has 231 
improved the extraction efficiency up to 45% with respect to previous studies using HLB cartridges. 232 
Nevertheless, better results for amoxicillin (from 18 to 36%) and  oxacillin (from 17 to 76%) could be 233 
obtained using Isolut ENV+ cartridges and water at pH 5 instead [54]. 234 
 235 
3.2. UPLC-MS/MS separation and determination of PhACs 236 
Fig. 3 shows two total ion current chromatograms obtained under optimized LC-MS conditions. 237 
Several solvents were tested as mobile phase to enhance the separation of target compounds by UPLC 238 
and their signal intensity in the mass analyzer. As many of the target compounds are characterized by 239 
basic behavior, the acid addition to aqueous mobile phase is commonly accepted [27, 51, 15]. 240 
Specifically, we could measure a signal improvement >70% for ceftiofur and tetracycline (ESI +) when 241 
using 10 mM of formic acid and ammonium formate buffer (pH 3.2) as aqueous phase, which ended up 242 
being the most appropriate solvent (Fig 3a). Most of the compounds analyzed under positive ionized 243 
conditions are usually protonated at low pH as the interaction between molecules and protons from the 244 
aqueous phase that leads to the formation of quasimolecular ion [M+H]
+
 is enhanced. Sometimes, the 245 
most abundant species [M+H]
+
 were accompanied by adducts such as [M+NH4]
+
 (e.g., ivermectin) and 246 
[M+Na]
+ 
(e.g., penicillin and
 
monensin) or double charge molecules [M+2H]
2+
 (e.g., spyramicin) (Table 247 
1). On the other hand, sensitivity considerably decreased when the pH was lowered by adding weak acids 248 
in negative ionization mode phase as other studies have already reported [15]. Slightly basic pH values 249 
improve deprotonation of molecules and enhance production of quasimolecular ions [M-H]
-
 when 250 
working in ESI- mode. Thus, we observed a signal decrease of >50% and 30% for triclosan and 251 
acethaminophen, respectively, when 0.1% of acetic acid was added. Increasing pH in the aqueous mobile 252 
phase yielded an appreciable increment in the intensity of peaks (between 50 and 60% for some 253 
compounds such as pravastatin and indomethacin) and improved their shape [27]. Therefore, 5mM of 254 
ammonium acetate and ammonia buffer (pH 8) was finally selected as the most favorable aqueous 255 
solution when operating in negative ionization mode (Fig. 3b).
 
Although peak shapes were enhanced 256 
using acetonitrile as organic solvent, methanol led to further enhancement in the signal intensity for most 257 
compounds (up to 70% for azithromycin and metronidazole) so this solvent was preferred over 258 
acetonitrile.  259 
Calibration curves from UPLC-QqQ-MS/MS had strong linearity (r
2
 > 0.9) for all target analytes. The 260 
instrumental limits of detection (iLOD) were <50 pg of the injected amount in 68% of cases and near 261 
90% of PhACs considered in this study showed values <1 ng L
-1
 for both detection (mLOD) and 262 
quantification (mLOQ) limits in real samples (Table 1). Detection and quantification limits were in the 263 
same range in other studies showing slightly better results in the present research. Anti-inflammatories 264 
mLOD in our study ranged from <0.1 to 1 ng L
-1
, reaching 2.4 ng L
-1
 for ketoprofen in a previous study 265 
[15]. Other groups, such as beta-blockers or psychiatric drugs followed the same trend being <0.1 ng L
-1 266 
for 99% of PhACs studied. A notable example could be the mLOD of 7.2 ng L
-1 
for tetracycline [15], 267 
quite separate from that found by this study (1 ng L
-1
). The reproducibility and repeatability of the method 268 
generated RSD of < 20%. 269 
 270 
3.3. Occurrence of PhACs in Huelva Estuary and Cadiz Bay 271 
To validate de applicability of the optimized analytical method, surface water samples from Huelva 272 
estuary and Cadiz bay (both located along the Gulf of Cadiz in SW Spain) were taken to the laboratory 273 
and analyzed. Tables 3 and 4 show the concentrations (in ng L
-1
)
 
of target compounds. Overall, 49 out of 274 
83 pharmaceuticals were detected in 75% of all collected samples. Their concentrations are usually 275 
between one and two orders of magnitude lower than those reported in river waters. For example, 276 
atenolol, salicylic acid and trimethoprim [34] were detected in Spanish rivers at levels between 234-1162 277 
ng L
-1
, significantly higher than those found in our sampling areas (<0.1-40.9 ng L
-1
). These differences 278 
are mostly due to frequent WWTP discharges in most European fresh water systems -often streams 279 
impacted by adjacent settlements along their courses- and the enhanced dilution experienced by chemicals 280 
once they reach coastal ecosystems. Other factors include weather, number of inhabitants and 281 
currents/tides. A more detail study on this topic was published by Benotti and Brownawell [37], where 282 
the authors developed a model to estimate the dilution effect in estuarine systems under wet and dry 283 
conditions, concluding that dilution is further increased in coastal system as a consequence of heavy rain 284 
events. In this sense, the concentration ratio of dry weather/wet weather was 3 and 20 for caffeine and 285 
trimethoprim, respectively, whereas other compounds such as nicotine and acetaminophen were below 286 
LOD during heavy rain episodes. Despite the dilution effect along the different sampling sites in all these 287 
studies, is also evident that concentrations of PhACs significantly increase in those stations located 288 
nearby sewage discharge outlets or areas where water circulation is restricted (e.g., M9 and M11 stations 289 
in Huelva Estuary).  290 
Figure 4 summarizes the average concentrations of different groups of antibiotics and other 291 
pharmaceuticals (see Table 1 for details on specific compounds per group) in Huelva Estuary and Cadiz 292 
Bay. Data on the stimulant caffeine was not included in the figure because of the considerably higher 293 
average concentrations measured for this compound (19.4-41.4 ng L
-1
) compared to the rest of analytes. 294 
These values for caffeine are in agreement with other data from studies in coastal waters (7-87 ng L
-1
) 295 
[36]. In fact, this compound has been considered by many authors as an excellent sewage markers that 296 
can be detected even in open waters from North Atlantic/Arctic oceans (7-9 ng L
-1
). Among non-297 
antibiotic PhACs, anti-inflammatories (6.7-9.6 ng L
-1
), beta-blockers (0.6-3.8 ng L
-1
), lipid regulators 298 
(1.1-5.9 ng L
-1
), and diuretics (0.6-16 ng L
-1
) were the most prominent groups of compounds in our 299 
sampling areas (Fig. 4b,d). Huelva Estuary usually showed higher concentrations for most of these 300 
chemicals than Cadiz Bay. As an example, concentrations near 200 ng L
-1
 for ibuprofen and in a range of 301 
1.1-69.7 ng L
-1
 for naproxen, 1.1 to 69.2 ng L
-1
 for gemfibrozil, and 1.8 to 167.6 ng L
-1
 for 302 
hydrochlorothiazide are in contrast with those measured for these PhACs in Cadiz Bay, which were 303 
below 20 ng L
-1
 at all sampling stations. These differences also occurred for the stimulant caffeine, which 304 
presented concentrations over 500 ng L
-1
 in Huelva and less than 50 ng L
-1
 in Cadiz. This disparity could 305 
be explained by the lower dilution in Huelva Estuary as opposed to the higher volume of water in Cadiz 306 
Bay, also more heavily affected by tidal currents. Nevertheless, there were some compounds, especially 307 
antibiotics, such as tetracyclines that were only identified in the Cadiz area (0.7-3.5 ng L
-1
) and 308 
quinolones, that were more prevalent in Huelva Estuary (up to 40 ng L
-1 
for norfloxacin, ciprofloxacin, 309 
and enrofloxacin), suggesting different consumption patterns and/or uses (e.g., aquiculture in Cadiz).  310 
In spite of the scarce information available, we can compare our data with those reported in a few 311 
coastal systems in United States and Europe. In general, we can observe that the same groups of PhACs 312 
are also predominant in Long Island Sound Estuary (LISE, NY), where average concentrations for anti-313 
inflammatories (0.1-50 ng L
-1
), beta-blockers (0.5-13 ng L
-1
), lipid regulators (0.2-29 ng L
-1
), and the 314 
diuretic hydrochlorothiazide (10 ng L
-1
) were in a similar range of those measured in SW Spain [40]. 315 
More specifically, some compounds such as bezafibrate (0.1-1.1 ng L
-1
), clofibric acid (0.5-0.6 ng L
-1
), 316 
and diclofenac (2.5-11.8 ng L
-1
) were within the same order of magnitude in Cadiz Bay, Huelva Estuary 317 
and LISE (0.7 ng L
-1
, 0.2 ng L
-1
 and 4 ng L
-1
 respectively). Regarding the occurrence of antibiotics, 318 
similar concentrations were also found in other estuary systems [43, 40, 39], being between 0.4 and 4 ng 319 
L
-1 
for quinolones (e.g., ciprofloxacin) and trimethoprim. On the other hand, there are also significant 320 
differences between US and EU regarding the ratios and occurrence of some specific PhACs, which could 321 
be attributed to different consumption/prescription patterns and authorized uses (veterinary vs health 322 
care). One example is the relatively high concentrations of some anti-inflammatories (e.g., naproxen up to 323 
50 ng L
-1
) and beta-blockers (e.g., metoprolol up to 150 ng L
-1
) that were measured in US West and East 324 
coasts [43, 39, 40], whereas these compounds are not detected in our study area. Antibiotics such as 325 
trimethoprim could not be found by Nödler and co-workers [39] but it was detected in more than 50% of 326 
our sampling stations (0.1-2 ng L
-1
). Regarding Asia, Fang and collaborators [38] analyzed surface coastal 327 
waters in Northern Taiwan, screening for some antiinflammatories such as ibuprofen (<2.5-57.1 ng L
-1
) 328 
and diclofenac (<2.5-53.6 ng L
-1
). These results are in contrast to those reported here from Huelva and 329 
Cadiz coastal waters, where concentrations of these compounds are significantly higher for ibuprofen and 330 
much lower for diclofenac (0.8-11.8 ng L
-1
).
  331 
 332 
4. CONCLUSION 333 
This study has contributed to expand the limited information available on the occurrence and 334 
distribution of pharmaceuticals in coastal waters. We have presented the optimization of an analytical 335 
method for the extraction and determination of 83 pharmaceuticals that includes the use of isotopically 336 
labelled compounds, SPE and triple quadrupole mass spectrometry detection. Due to the wide range of 337 
analytes considered and their different physicochemical properties, their extraction from aqueous samples 338 
was preferred at acid and neutral pH values to achieve proper recoveries (more than 80% for half of the 339 
compounds). Separation and quantification of target PhACs were also performed in two different runs as 340 
different ionization modes (ESI+ and -) were required. Two different buffers (10 mM of formic acid and 341 
ammonium formate, and 5mM of ammonium acetate and ammonia) were also used as mobile aqueous 342 
phases to achieve highest sensitivity and better peak shapes. Once optimized, the method detection limits 343 
were within a few ng L
-1
 or below for all analytes. The application of the method for the analysis of 344 
surface water samples from Huelva Estuary and Cadiz Bay (SW Spain) has revealed the predominance of 345 
some compounds such as metronidazole (a nitroimidazol at an average concentration of 7-7.8 ng L
-1
), 346 
ofloxacin (a quinolone at 2-3.5 ng L
-1
), atenolol (a beta-blocker at 0.8-3.7 ng L
-1
) and several anti-347 
inflammatories: ibuprofen (4.3-15.6 ng L
-1
), mefenamic acid (5.2-16.8 ng L
-1
), fenoprofen (1.9-12.2 ng L
-348 
1
), and diclofenac (0.8-11.8 ng L
-1
). Concentrations of many of the target compounds were consistent with 349 
previous studies in other European and American coastal and estuarine systems, but some differences 350 
among specific compounds reveals different consumption/uses patterns.  351 
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Figure 1. Map showing the location of the sampling stations along the Gulf of Cadiz in Huelva Estuary 505 
(Fig.1a) and the Cadiz Bay (Fig.1b). 506 
 507 
 508 
 509 
 510 
Figure 2. Optimized SPE parameters, a) pH 7 using 60 mg cartridge and elution using methanol; b) pH 7 511 
using 500 mg cartridge and elution using methanol; c) pH 2 using 500 mg cartridge and elution using 512 
methanol; d) pH 7 using 500 mg cartridge, adding 1g of EDTA and elution using methanol 1% formic 513 
acid; e) pH 2 using 500 mg cartridge, adding 1g of EDTA and elution using methanol with 1% formic 514 
acid.  515 
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Figure 3. Representative total ion current (TIC) chromatograms of a 25 ng mL
-1
 standard mixture of the 555 
compounds analyzed under positive (a) and negative (b) ionization.  556 
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Figure 4. Average concentrations (in ng L
-1
) of (a,c) antibiotics and (b,d) PhACs in  Huelva Estuary and 580 
the Bay of Cadiz, respectively. 581 
  582 
Huelva Cadiz 
Table 1. UPLC-MS/MS parameters (ionization mode, retention time, MRM transitions and limits of detection) for the 
analysis of target PhACs and their corresponding isotopically labelled compounds. Suppliers are also indicated. 
PhACs group Compound 
tR  
(min) 
MRM 
Collision 
Energy 
iLOD 
(pg) 
mLOD 
(ng L-1) 
mLOQ 
(ng L-1) 
 Amoxicillina1 (+) 1.77 366.10>349.20 6 309,3 0,9 2,9 
   366.10>114.30 20    
 Penicillin-Ga1 (+) 3.64 357.00>198.20* 12 681,8 0,4 1,3 
Penicillins   357.00>182.00 14    
 Oxacillina1 (+) 3.89 402.10>160.40 11 16,1 <0.1 0,2 
   402.10>243.40 11    
 Ampicillina1 (+) 2.72 350.10>106.30 15 5,0 <0.1 <0.1 
   350.10>160.40 11    
 Cefaclora1 (+) 2.58 368.00>174.40 13 10,3 <0.1 <0.1 
   368.00>106.40 19    
 Cefdinira1 (+) 2.31 396.00>227.10 11 69,8 0,1 0,3 
   396.00>126.10 26    
Cephalosporins Ceftiofura1 (+) 3.34 524.04>241.20 15 15,5 <0.1 0,1 
   524.04>209.90 22    
 Cefadroxila1 (+) 1.82 363.30>114.30 13 21,5 <0.1 0,1 
   363.30>208.30 8    
 Cefquinomea1 (+) 2.39 529.00>134.40 13 34,1 <0.1 <0.1 
   529.00>396.40 9    
 Doxyciclinea2 (+) 2.91 445.20>410.40 21 142,6 0,2 0,5 
   445.20>267.60 35    
 Oxytetracyclinea2 (+) 2.99 461.10>425.20 20 72,8 <0.1 0,1 
Tetracyclines   461.10>426.90 19    
 Chlortetracyclinea2 (+) 3.43 479.10>444.10 20 24,0 <0.1 0,1 
   479.10>462.10 15    
 Tetracyclinea2 (+) 3.67 445.20>428.20 10 2097,9 1,0 3,5 
        
 Tiamulina1 (+) 4.05 494.30>191.40 19 4,4 <0.1 <0.1 
Amphenicols   494.30>193.10 19    
 Chloramphenicola1 (-) 2.73 321.00>152.10 16 14,3 <0.1 <0.1 
   321.00>257.50 8    
 Erythromycina3 (+) 4.16 734.50>158.20 31 66,6 <0.1 0,1 
   734.50>575.40 20    
 Clarithromycina3 (+) 4.49 748.48>158.10 26 0,4 <0.1 <0.1 
   748.48>590.20 18    
 Azithromycina3 (+) 4.43 748.90>591.40 26 1,0 <0.1 <0.1 
Macrolides        
 Roxithromycina3 (+) 4.51 837.50>158.30 32 1,7 <0.1 <0.1 
   837.50>679.50 20    
 Spiramycina3 (+) 3.40 422.00>174.30* 20 74,3 0,1 0,5 
   422.00>101.20 18    
 Tylosina3 (+) 4.08 916.50>174.20 39 6,8 <0.1 <0.1 
   916.50>771.80 29    
 Lincomycina1 (+) 2.66 407.20>126.30 24 0,6 <0.1 <0.1 
Lincosamides   407.20>359.40 16    
 Clindamycina1 (+) 3.83 425.20>126.30 26 5,4 <0.1 <0.1 
   425.20>377.40 16    
 Sulfamethazinea4 (+) 2.72 279.10>186.20 19 26,8 <0.1 0,1 
   279.10>92.30 32    
 Sulfamethizolea4 (+) 2.64 271.03>156.10 13 25,0 <0.1 0,1 
   271.03>92.40 29    
 Sulfathiazolea4 (+) 2.26 256.02>156.20 14 2,2 <0.1 <0.1 
   256.02>108.30 23    
 Sulfadiazinea4 (+) 2.09 251.06>155.20 15 11,5 <0.1 <0.1 
   251.06>92.30 26    
 Sulfamethoxazolea4 (+) 2.86 254.06>156.10 15 13,6 <0.1 <0.1 
   254.06>91.40 16    
 Sulfamethoxypyridazinea4 (+) 2.75 281.07>156.10 16 13,0 <0.1 <0.1 
Sulfonamides   281.07>92.90 29    
 Sulfadimethoxinea4 (+) 3.35 311.08>156.80 24 7,7 <0.1 <0.1 
   311.08>92.00 40    
 Sulfisoxazolea4 (+) 2.99 268.07>156.00 13 12,4 <0.1 <0.1 
   268.07>92.10 25    
 Sulfaguanidinea4 (+) 1.11 215.06>156.40 13 27,8 <0.1 0,1 
   215.06>92.30 24    
 Sulfanilamidea4 (+) 1.31 173.03>156.20 6 447,8 0,4 1,2 
   173.03>92.20 18    
 Flumequinea5 (+) 4.00 262.10>243.20 17 3,1 <0.1 <0.1 
   262.10>244.90 16    
 Norfloxacina5 (+) 2.77 320.10>302.20 19 71,4 <0.1 0,1 
   320.10>231.20 40    
 Ofloxacina5 (+) 2.72 362.10>318.90 17 0,2 <0.1 <0.1 
   362.10>317.10 17    
Quinolones Ciprofloxacina5 (+) 2.83 332.10>314.80 21 140,2 0,1 0,2 
   332.10>313.30 21    
 Enrofloxacina5 (+) 2.83 360.10>342.20 19 22,1 <0.1 <0.1 
   360.10>316.20 16    
 Sparfloxacina5 (+) 3.15 393.20>349.20 17 4,8 <0.1 <0.1 
   393.20>375.20 18    
 Danofloxacina5 (+) 2.83 358.10>340.80 22 88,8 0,1 0,2 
   358.10>339.10 23    
Aminocoumarin 
antibiotic 
Novobiocina5 (+) 5.06 613.20>189.30 27 
9,1 <0.1 <0.1 
   613.20>133.40 57    
 
Nitrofurantoina1 (+) 1.99 
239.00>122.20 
(-) 
19 
1071,4 1,5 5,0 
   239.00>95.70 12    
Nitroimidazols Metronidazolea1 (+) 2.23 172.10>128.80 14 44,9 <0.1 0,1 
   172.10>82.30 27    
 Ornidazolea1 (+) 3.02 220.05>128.10 14 10,4 <0.1 <0.1 
   220.05>82.40 27    
 Trimethoprima6 (+) 2.64 291.10>229.20 24 1,0 <0.1 <0.1 
   291.10>122.40 25    
 Monensina1 (+) 5.82 688.00>636.00* 10 3,5 <0.1 <0.1 
Other    688.00>617.00 30    
antibiotics Ivermectina1 (+) 6.06 892.00>569.40* 12 48,4 0,2 0,5 
   892.00>307.00 23    
 Rifampicina1 (+) 4.32 823.40>791.50 14 51,4 0,1 0,2 
   823.40>399.10 23    
 Triclocarbana7 (-) 3.39 315.10>161.90 11 9,6 <0.1 0,1 
Antibacterials   315.10>159.90 12    
 Triclosanb8 (-) 3.44 286.70>35.80 5 1,8 <0.1 <0.1 
 Phenazonea9 (+) 3.02 189.00>77.30 44 132,2 0,1 0,2 
   189.00>55.50 28    
 Phenylbutazonea10 (-) 2.85 308.00>131.00 21 1153,8 0,8 2,8 
   308.00>280.20 16    
 Acethaminophena11 (-) 1.90 150.00>107.80 21 1209,7 0,5 1,8 
   150.00>106.00 13    
 Salicylic Acida10 (-) 1.96 137.00>93.40 10 2777,8 1,3 4,4 
   137.00>65.90 19    
 Ketoprofena9 (+) 4.40 255.20>209.30 11 25,5 0,1 0,3 
   255.20>105.20 20    
Antiinflammatories Naproxena10 (-) 2.73 229.10>169.10 16 595,2 0,3 0,9 
   229.10>185.20 4    
 Ibuprofena12 (-) 2.96 205.10>160.00 5 2272,7 1,0 3,5 
   205.10>162.10 5    
 Fenoprofena10 (-) 2.90 241.10>197.10 5 351,3 0,1 0,5 
   241.10>93.40 32    
 Indomethacina10 (-) 2.96 358.10>312.10 6 1239,7 0,6 2,1 
   356.10>297.20 14    
 Diclofenaca10 (-) 2.93 294.00>250.00 7 113,2 0,1 0,2 
   294.00>36.00 22    
 Mefenamic acida10 (-) 2.96 240.10>196.90 14 11,8 <0.1 <0.1 
   240.10>180.10 23    
 Atenolola1 (+) 2.01 267.19>145.10 28 2,5 <0.1 <0.1 
   267.19>72.80 22    
 Metoprolola1 (+) 3.15 268.40>116.20 17 94,9 0,1 0,2 
   268.40>74.20 20    
 Propanolola1 (+) 3.80 260.10116.20 17 33,3 <0.1 0,1 
Beta-blockers   260.10>72.90 21    
 Timolola1 (+) 3.18 317.10>261.10 15 0,4 <0.1 <0.1 
   317.10>74.40 22    
 Nadolola1 (+) 2.72 310.20>254.20 16 2,8 <0.1 <0.1 
   310.20>201.10 22    
 Pindolola1 (+) 2.50 249.10>116.90 17 39,3 <0.1 0,1 
   249.10>115.40 16    
 Famotidinea1 (+) 2.07 338.00>189.80 19 16,5 <0.1 0,1 
Histamine    338.00>188.20 19    
receptor antagonist Ranitidinea1 (+) 2.01 315.00>129.40 31 18,9 <0.1 0,1 
   315.00>130.80 31    
 Carbamazepinea13 (+) 4.05 237.10>193.80 22 7,6 <0.1 <0.1 
   237.10>192.40 31    
Psychiatric drugs Fluoxetinea14 (+) 4.32 310.10>44.60 10 3,9 <0.1 <0.1 
and estimulants   310.10>148.40 7    
 Amitriptilinea13 (+) 4.29 278.20>91.20 27 47,9 <0.1 0,1 
        
 Caffeinea1 (+) 2.72 195.10>137.30 17 105,6 0.1 0.3 
   195.10>138.90 18    
 Clofibric acida15 (-) 2.76 213.03>127.90 12 106,8 0.1 0,2 
   213.03>85.50 10    
 Gemfibrozila15 (-) 3.04 249.10>120.70 11 11,8 <0.1 <0.1 
   249.10>121.70 11    
Lipid Regulators Fenofibratea15 (+) 5.46 361.10>232.00 15 6,2 <0.1 0,1 
   361.10>139.20 27    
 Bezafibratea15 (-) 2.82 360.10>274.20 14 2,3 <0.1 <0.1 
   360.10>85.50 13    
 Pravastatina15 (-) 2.76 423.00>101.90 26 50,6 <0.1 0,1 
   423.00>100.40 25    
 Hydrochloroth. a18 (-) 1.73 295.90>269.10 17 4,3 <0.1 <0.1 
   295.90>205.20 22    
Diuretics Furosemidea1 (-) 2.47 328.90>205.00 20 18,6 <0.1 <0.1 
   328.90>285.10 12    
 Albuterola16 (+) 2.01 240.10>148.20 17 64,4 <0.1 0,1 
   240.10>222.30 7    
Other  Glibenclamidea17 (+) 4.76 494.10>369.20 12 1,8 <0.1 <0.1 
PhACs   494.10>169.10 38    
 Metotrexatea1 (+) 2.50 455.18>175.20 47 29,4 <0.1 0,1 
   455.18>307.10 24    
 1.Atenolol-d7
d (+) 2.01 274.20>146.00 26    
   274.20>144.50 26    
 583 
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 585 
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 587 
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 2.Demeclocyclinea (+) 3.15 465.10>448.10 17    
   465.10>430.20 23    
 3.Erythromycin-d3
a (+) 4.16 738.90>162.00 33    
   738.90>581.10 20    
 4.Sulfadimethoxine-d6
a (+) 3.34 317.40>155.80 19    
   317.40>92.00 29    
 5.Ofloxacin-d3
a (+) 2.72 365.20>261.00 30    
   365.20>320.90 18    
 6.Trimethoprim-d9
a (+) 2.58 301.00>235.10 25    
   301.00>123.90 25    
 7.Triclocarban 13C6
f (-) 3.39 319.00>159.90 12    
   321.00>161.90 15    
 8.Triclosan-d3
b (-) 3.44 291.60>35.50 5    
        
 9.Phenazone-d3
d
 (+) 3.02 192.00>59.30 24    
Isotopically    192.00>77.20 34    
labelled  10.Naproxen methoxy-d3
a (-) 2.73 232.20>169.90 16    
compounds        
 11.Acethaminophen-d4
d (-) 1.90 154.19>111.00 17    
        
 12.Ibuprofen-d3
d (-) 2.96 208.30>164.00 3    
        
 13.Carbamazepine-d10
e (+) 4.05 247.20>204.50 23    
   247.20>203.10 23    
 14.Fluoxetine-d5
a (+) 4.32 315.00>153.00 10    
        
 15.Gemfibrozil-d6
e (-) 3.04 255.20>120.50 11    
        
 16.Albuterol-d3
a (+) 2.01 243.33>150.90 18    
   243.33>224.90 8    
 17.Glibenclamide-d3
e (+) 4.76 498.03>372.80 16    
   498.03>171.80 37    
 18.Hydrochlorothiazide 13C6
a (-) 1.73 302.70>256.50 4    
   302.70>210.90 22    
a Sigma-Aldrich, 
b Dr. Ehrenstorfer GmbH, c Clariant Produkte, d LGC Standards, eCDN Isotopes S.A., fCambridge Isotope Laboratories. Inc. 
* 
Quasimolecular ions different from [M+H]+: penicillin and monensin: [M+Na]+, spyramycin: [M+2H]2+, ivermectin: [M+NH4]
+. 
  Isotopically labelled compounds are indicated by numerated superscript for each compound. 
        
Table 2. Extraction recovery percentages for PhACs by 
SPE 
    
Compound 
Recovery 
(%) 
Compound 
Recovery 
(%) 
Amoxicillin  18±3 Nitrofurantoin* 36±10 
Penicillin-G 86±34 Metronidazole 78±22 
Oxacillin 17±3 Ornidazole 60±16 
Ampicillin 51±12 Trimethoprim 90±21 
Cefaclor 41±11 Monensin 86±6 
Cefdinir 34±13 Ivermectin 15±4 
Ceftiofur 45±15 Rifampicin 36±5 
Cefadroxil 27±11 Triclocarban 20±1 
Cefquinome 49±19 Triclosan 53±0 
Doxycicline 47±11 Phenazone 110±17 
Oxytetracycline* 84±24 Phenylbutazone 68±12 
Chlortetracycline* 57±20 Acethaminophen 113±5 
Tetracycline* 100±15 Salicylic Acid 106±11 
Tiamulin 70±16 Ketoprofen 17±4 
Chloramphenicol 97±1 Naproxen 115±7 
Erythromycin 92±15 Ibuprofen 109±9 
Clarithromycin 69±17 Fenoprofen 117±17 
Azithromycin 81±27 Indomethacin 100±5 
Roxithromycin 81±27 Diclofenac 106±8 
Spiramycin 27±4 Mefenamic acid 101±13 
Tylosin 68±12 Atenolol 97±6 
Lincomycin 73±10 Metoprolol 64±16 
Clindamycin 44±11 Propanolol 70±5 
Sulfamethazine 69±9 Timolol 68±15 
Sulfamethizole 76±17 Nadolol 77±9 
Sulfathiazole 93±14 Pindolol 66±19 
Sulfadiazine 89±31 Famotidine 38±17 
Sulfamethoxazole 93±18 Ranitidine 22±11 
Sulfamethoxyp. 81±19 Carbamazepine 104±15 
Sulfadimethoxine 109±23 Fluoxetine* 80±18 
Sulfisoxazole 78±22 Amitriptiline* 100±7 
Sulfaguanidine 65±5 Caffeine 68±12 
Sulfanilamide 62±0 Clofibric acid 73±3 
Flumequine* 79±32 Gemfibrozil 97±5 
Norfloxacin* 94±24 Fenofibrate 17±4 
Ofloxacin* 81±18 Bezafibrate 64±6 
Ciprofloxacin* 111±27 Pravastatin 65±3 
Enrofloxacin* 80±26 Albuterol 113±7 
Sparfloxacin* 101±12 Glibenclamide  146±9 
Danofloxacin* 87±12 Metotrexate 72±17 
Novobiocin 31±10 Hydrochlorot. 112±5 
  Furosemide 108±22 
    * pH2 591 
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Table 3. Concentrations of target PhACs in Huelva water samples (ng L-1). Only those compounds that were detected are shown here. 
Compound O1 O2 O4 M1 M2 M3 M4 M5 M6 M7 M9 M10 M11 T1 T2 T3 J1 J3 J5 J7 
Tiamulin 0.5 0.6 0.8 0.6 0.6 0.6 0.6 0.6 0.6 1.3 0.7 0.7 0.7 0.4 0.5 0.9 0.7 0.8 0.7 0.8 
Chloramphenicol 8.1 5.0 10.6 3.5 5.6 4.0 5.6 4.1 4.7 3.6 3.6 7.0 2.9 13.8 6.8 3.2 3.8 8.3 3.5 5.9 
Erythromycin <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Lincomycin 0.8 0.4 0.5 0.7 0.4 0.4 0.4 0.4 0.3 0.5 0.6 0.6 0.4 0.5 0.8 0.7 0.6 0.5 0.6 0.6 
Clindamycin 1.0 0.9 1.1 0.9 1.0 1.6 1.1 0.9 1.0 2.2 1.4 1.3 1.5 1.0 1.3 3.8 2.4 <LOD 1.8 1.4 
Sulfamethazine 0.8 0.3 0.4 0.5 0.4 0.4 0.5 0.5 0.4 0.6 0.5 0.8 0.8 0.7 0.4 0.4 0.7 0.6 1.0 0.9 
Sulfamethizole 0.2 <LOD <LOD <LOD <LOD 0.1 <LOQ <LOD <LOD <LOD <LOQ <LOD 0.2 <LOQ 0.3 <LOD 0.1 <LOD <LOD <LOD 
Sulfathiazole 0.4 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.4 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 
Sulfadiazine 0.3 0.1 0.1 <LOQ 0.1 0.1 0.1 0.1 <LOQ 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 <LOQ 0.1 0.2 
Sulfamethoxazole 0.9 0.1 0.1 0.03 0.3 0.1 <LOD 0.1 <LOD <LOD 15.5 0.3 4.8 0.7 1.7 0.7 0.6 0.3 0.3 0.4 
Sulfamethoxypyridacine 0.3 <LOD <LOD 0.1 <LOQ <LOQ 0.1 <LOD <LOD 0.1 <LOQ 0.1 <LOD <LOQ <LOD <LOD <LOQ <LOD 0.1 0.4 
Sulfadimethoxine 0.6 0.3 0.3 0.5 0.4 0.3 0.5 0.3 0.4 0.4 0.3 0.4 0.5 0.3 0.4 <LOD 0.4 0.4 0.5 0.5 
Sulfanilamide <LOD <LOD <LOQ <LOD <LOQ <LOQ <LOQ <LOQ <LOD <LOQ <LOQ <LOD <LOQ <LOQ 1.8 <LOQ <LOQ <LOD <LOD <LOD 
Flumequine 1.1 0.4 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.7 0.2 0.3 0.1 0.1 0.1 0.5 0.3 0.2 0.3 0.1 
Norfloxacin 42.9 8.2 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Ofloxacin 28.0 6.7 4.4 1.9 2.0 5.7 2.8 2.2 2.0 4.0 1.9 2.6 1.7 1.8 7.5 8.0 4.9 2.6 4.2 2.7 
Ciprofloxacin 47.5 7.2 3.3 2.2 1.4 3.0 1.8 <LOD 0.8 3.7 1.6 1.8 1.1 1.4 <LOD 6.4 5.7 <LOD 3.5 <LOD 
Enrofloxacin 61.7 14.9 6.2 3.3 4.9 4.4 4.2 2.9 2.5 6.3 7.0 3.8 <LOD <LOD <LOD <LOD 4.4 3.5 3.8 3.0 
Sparfloxacin 11.9 2.9 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Danofloxacin 77.3 17.1 8.1 3.0 4.6 5.0 3.2 2.0 2.7 6.2 4.7 5.5 3.2 1.0 5.5 <LOD 3.8 2.6 5.0 3.3 
Metronidazole 16.3 9.8 9.1 10.4 9.6 9.2 9.9 8.6 9.6 8.6 10.7 9.0 10.0 9.3 10.0 8.4 8.3 8.1 12.1 11.8 
Nitrofurantoin 
<LOD <LOD <LOD <LOD <LOD 18.56 <LOD <LOD <LOD <LOD 
<LOD
<LOD 46.88 <LOD <LOD <LOD <LOD <LOD <LOD <LOD 17.6 
Trimethoprim 0.5 <LOD 0.3 <LOD <LOD 0.1 0.8 0.7 <LOD 1.1 0.1 1.6 1.0 0.8 2.0 0.2 2.0 0.3 1.8 0.6 
Monensin 
0.3 <LOQ <LOD 0.1 <LOD <LOD <LOD <LOQ 
<LOD
- <LOD <LOD 0.2 <LOQ <LOQ 0.1 <LOD 0.3 <LOQ 0.4 0.1 
Triclocarban <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 1.3 <LOD <LOD 
Triclosan <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 7.9 <LOD <LOD 
Acethaminophen <LOD <LOQ <LOQ <LOQ <LOD <LOD <LOQ <LOQ <LOQ <LOQ 2.0 2.2 33.7 11.4 75.6 13.6 <LOQ <LOD <LOQ <LOD 
Diclofenac 1.9 <LOD 7.8 <LOD <LOD <LOD  <LOD 1.5 <LOD <LOD 3.1 <LOD 5.5 9.2 10.7 2.2 1.6 6.2 <LOD 0.3 
Fenoprofen 5.9 6.5 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 6.9 7.5 6.7 <LOD <LOD <LOD 8.7 20.6 8.3 7.2 
Ibuprofen <LOD 8.8 <LOD 9.0 8.4 8.5 6.9 8.2 8.7 4.3 181.8 11.3 195.0 33.7 136.0 39.6 15.3 9.3 <LOQ <LOD 
Indomethacin <LOQ 2.2 2.5 3.2 2.4 <LOQ 2.5 2.3 2.1 <LOQ <LOQ 2.5 <LOD 7.7 5.8 4.1 3.6 3.6 3.4 <LOQ 
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Mefenamic acid 7.5 8.9 10.8 12.2 8.0 11.0 8.2 12.7 9.8 14.6 6.5 10.9 8.8 24.6 14.8 7.5 17.6 29.2 12.7 13.3 
Naproxen 3.2 2.8 1.8 4.0 3.3 4.7 3.7 3.1 3.3 1.1 69.7 4.8 57.3 15.2 35.9 12.5 4.3 5.7 2.0 <LOD 
Phenylbutazone 3.4 <LOD <LOD <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 2.80 2.89 <LOQ 1.44 2.85 <LOQ 3.07 
Salicilic acid 17.5 5.5 13.7 6.0 4.7 <LOQ 6.4 5.1 8.5 6.4 5.5 5.9 15.8 16.3 10.5 5.5 7.8 29.4 4.9 4.3 
Atenolol 4.0 3.3 3.3 1.9 2.4 3.4 2.6 2.5 2.5 0.5 24.9 2.7 40.9 9.1 21.7 15.8 4.2 2.8 2.1 0.3 
Nadolol <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 0.5 <LOD 0.9 0. <LOD 0.6 <LOD 0.1 <LOD <LOD 
Carbamazepine 0.6 0.4 0.3 0.4 0.3 0.3 0.2 0.3 0.3 0.1 0.9 0.3 1.6 0.7 1.1 1.0 0.5 0.4 0.4 0.2 
Amitriptiline 0.3 0.4 0.6 <LOD <LOD <LOD <LOD <LOD <LOD <LOD 0.5 <LOD <LOD 0.2 0.4 0.3 0.2 <LOD <LOD <LOD 
Caffeine 39.6 17.4 13.2 20.9 21.8 15.7 11.3 52.1 20.1 10.5 182.3 20.2 522.0 30.2 107.8 59.0 20.7 18.4 25.8 7.2 
Gemfibrozil 1.5 6.6 1.1 9.0 6.9 6.7 5.4 6.8 5.1 1.2 46.7 9.1 64.8 29.8 69.2 22.3 12.8 8.9 5.8 1.4 
Bezafibrate <LOD 0.6 <LOD 0.4 0.4 0.6 0.5 0.4 0.3 <LOD 5.6 0.4 5.2 2.2 2.8 1.3 0.5 0.6 0.2 <LOD 
Clofibric acid 0.5 1.4 <LOD 0.4 0.4 0.3 0.3 0.3 0.3 0.3 0.7 0.4 0.8 1.5 2.2 0.9 0.4 0.9 0.3 0.2 
Furosemide 8.4 7.4 9.5 1.0 1.0 6.5 6.1 5.3 4.9 1.8 10.6 <LOD 8.2 5.7 29.8 4.5 6.1 11.0 2.3 <LOD 
Hydrochlorothiazide 3.8 4.1 1.8 1.8 1.4 3.5 2.1 3.0 2.6 <LOD 20.7 4.1 41.0 63.1 167.6 38.8 7.9 3.8 2.0 <LOD 
Table 4. Concentrations of target PhACs in Cadiz water samples (ng L-1). Only those compounds that were detected are shown here.  
Compound E0 E6 E8 P1 R7 S8 T6 U2 U4 U8 V1 W2 W6 W7 X3 X5 Y4 
Doxycicline <LOD <LOD <LOD 3.5 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Oxytetracycline <LOD <LOD <LOD 2.3 <LOD <LOD 2.4 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Tetracycline 1.4 0.7 1.7 1.6 2.2 1.4 1.9 1.4 0.7 0.9 1.8 1.5 1.5 0.8 1.3 1.1 2.4 
Tiamulin 0.7 0.7 0.8 0.6 1.0 1.2 4.5 0.8 1.0 0.8 0.7 0.5 0.6 0.7 0.5 1.1 0.6 
Chloramphenicol 3.0 1.9 2.4 2.2 1.7 2.0 <LOD 5.0 2.7 6.0 1.5 <LOD <LOD 4.3 2.8 2.9 2.1 
Erythromycin <LOD <LOD <LOD <LOD <LOQ <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Lincomycin 0.2 0.5 0.2 0.2 0.7 0.3 0.4 0.5 0.3 0.6 0.3 0.3 0.2 0.1 0.5 0.2 0.2 
Clindamycin 1.2 1.3 1.4 1.0 1.3 2.0 3.2 1.2 1.5 1.3 1.2 1.0 1.1 1.6 0.9 9.6 0.8 
Sulfamethazine 0.3 0.9 0.4 0.3 0.3 0.4 0.3 0.5 0.3 0.2 0.3 0.1 02 0.3 0.5 0.1 0.5 
Sulfamethizole <LOD 0.1 <LOD <LOD 0.1 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Sulfathiazole 0.4 0.5 0.3 0.3 0.4 0.4 0.3 0.4 0.5 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
Sulfadiazine 0.54 0.3 0.1 0.2 0.3 0.5 0.3 0.2 0.3 0.3 0.3 0.1 0.1 0.1 0.3 0.2 0.1 
Sulfamethoxazole <LOD 0.2 <LOQ <LOD 0.2 <LOD <LOD 0.1 0.1 <LOD <LOD <LOD <LOD <LOD 0.1 <LOD <LOD 
Sulfamethoxypyridacine <LOD 0.5 <LOD <LOD 0.4 <LOD <LOD <LOQ 0.2 <LOQ <LOD <LOD <LOD <LOD 0.1 <LOD <LOD 
Sulfadimethoxine 0.4 0.7 0.3 0.4 0.7 0.5 0.3 0.5 0.5 0.5 0.3 0.3 0.3 0.4 0.4 0.3 0.4 
Norfloxacin 8.7 5.8 2.9 5.2 1.9 <LOD 8.6 1.2 2.6 6.1 <LOD 2.1 2.3 3.8 <LOD 4.9 1.0 
Ofloxacin 3.1 3.2 2.5 4.2 <LOD 2.8 8.5 3.5 31 4.8 2.1 1.3 <LOD 1.7 <LOD 4.2 <LOD 
Ciprofloxacin <LOD <LOD <LOD 2.2 <LOD <LOD 6.9 4.6 <LOD 6.1 <LOD <LOD <LOD <LOD <LOD <LOD <LOD 
Enrofloxacin <LOD <LOD 3.4 3.2 <LOD <LOD 9.1 <LOD <LOD <LOD 3.1 <LOD 15.4 <LOD 1.9 6.7 <LOD 
Danofloxacin 1.4 1.8 2.8 5.0 3.0 <LOD 10.0 3.4 4.1 6.0 2.6 <LOD <LOD <LOD <LOD <LOD <LOD 
Metronidazole 8.2 11.1 7.7 6.5 13.6 9.7 7.8 14.8 11.2 7.5 9.4 7.1 6.0 9.3 7.0 5.4 8.5 
Ornidazole <LOD <LOD <LOD <LOD <LOD <LOD 1.4 0.1 <LOD <LOQ <LOD <LOD <LOD <LOQ <LOD <LOD <LOD 
Nitrofurantoin <LOD <LOD <LOD <LOD 12.4 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 9.6 <LOD <LOD 
Trimethoprim <LOD 0.3 <LOD <LOD <LOD <LOD 1.9 0.5 <LOQ <LOD <LOD <LOD <LOD <LOD <LOD 3.3 <LOD 
Monensin 0.1 0.1 0.2 0.3 0.3 0.2 0.3 0.3 0.1 0.2 0.6 0.4 0.3 0.2 0.3 1.0 0.3 
Triclocarban 0.9 0.4 0.4 1.1 0.8 0.7 <LOD 1.0 0.7 0.3 <LOD <LOQ 0.2 <LOD 1.3 0.7 0.4 
Triclosan 3.6 0.6 <LOQ 3.6 6.3 6.9 4.9 16.1 1.0 2.8 1.3 4.2 1.9 0.02 4.6 11.3 5.7 
Acethaminophen 2.6 <LOQ 8.0 5.4 0.6 <LOD 6.4 <LOQ <LOD <LOQ 3.9 7.1 2.6 <LOD 2.6 <LOQ <LOD 
Diclofenac 12.5 3.9 3.1 9.0 12.9 16.0 12.1 4.1 5.1 13.5 21.2 <LOD 9.1 4.2 26.0 6.1 27.6 
Fenoprofen 31.9 <LOD 7.7 4.4 8.3 29.6 11.7 17.7 2.6 16.7 20.2 <LOD <LOD 14.8 5.8 <LOD 25.7 
Ibuprofen 4.5 <LOQ 18.3 4.4 3.4 <LOQ 4.5 2.8 <LOD <LOQ 7.8 6.3 3.5 <LOQ 4.9 <LOQ 3.7 
Indomethacin <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOQ <LOD <LOQ <LOQ 3.79 
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Mefenamic acid 25.5 4.7 15.9 12.0 14.9 20.3 24.0 15.7 7.6 15.2 27.6 17.5 16.3 11.2 18.9 13.3 19.3 
Naproxen 1.3 <LOD 2.6 2.2 1.0 0.9 2.6 1.2 <LOD <LOD 2.3 2.5 2.1 <LOD 1.7 1.3 <LOD 
Phenylbutazone 3.6 <LOD <LOQ <LOQ <LOQ <LOQ 4.7 7.9 <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ <LOQ 
Salicilic acid 7.7 <LOQ 12.6 12.9 6.6 15.8 12.4 5.5 <LOQ 6.3 13.6 13. 12.9 6.6 13.5 11. 14.4 
Atenolol 0.4 0.3 0.9 0.6 0.9 0.2 0.8 0.6 0.2 0.3 0.6 0.7 0.4 0.3 0.4 0.2 2.8 
Carbamazepine 0.3 0.3 0.3 0.2 0.3 0.4 0.3 0.2 0.4 0.3 0.3 0.2 0.3 0.3 0.2 0.3 0.2 
Caffeine 11.9 12.3 24.3 15.9 37.9 15.6 20.8 11.7 9.8 14.2 17.3 23.0 42.9 11.8 16.8 14.6 15.21 
Gemfibrozil 2.1 0.8 4.2 3.2 2.4 2.1 5.0 1.0 0.7 2.4 3.4 4.8 5.8 1.2 3.9 1.9 1.7 
Bezafibrate <LOD 0.1 0.3 0.3 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.3 0.1 <LOD 0.2 <LOD <LOD 
Clofibric acid 0.7 0.2 1.3 0.2 0.7 0.4 0.9 0.5 0.4 0.5 0.7 <LOD 0.6 0.4 0.4 0.3 0.8 
Furosemide 0.7 <LOD 0.2 <LOD 0.4 <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD <LOD 2.0 1.6 <LOD 
Hydrochlorothiazide 0.3 <LOD 1.8 1.4 0.6 <LOD 1.4 <LOD <LOD <LOD 1.1 1.8 1.6 0.3 1.6 1.3 1.0 
